Onkologie, Hämatologie - Daten und Informationen

Literatur zu Kapitel 4.5: Metastasentherapie des malignen Melanoms

Autor/en: R. Stadler
Letzte Änderung: 01.12.2006
  • Adam J, Habeshaw T, Kirk J.
    Response rate of malignant melanoma to large fraction irradiation.
    Br J Radiol 1982;55:605-607.

  • Agarwala SS et al.
    Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study.
    J Clin Oncol 2004;11:2101-2107.

  • Amer M, Al-Sarraf M, Vaitkevicius V.
    Clinical presentation, natural history and prognostic factos in advanced malignant melanoma.
    Surg Gynecol Obstet 1979;14:687-692.

  • Amer MH et al.
    Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival.
    Cancer 1978;42:660-668.

  • Anrews DW et al.
    Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RT06 9508 randomized trial.
    Lancet 2004;363:1665-1672.

  • Arcangeli G et al.
    Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration.
    Int J Radiat Oncol Biol Phys 1998;42:1119-26.

  • Brega K et al.
    Surgical treatment of brain metastases in malignant melanoma.
    Cancer 1990;66:2105-2110.

  • Brock CS et al.
    Phase I trial of temozolomide using an extended continous oral schedule.
    Cancer Res 1998;58:4363-4367.

  • Brocker EB et al., Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: Report on a pilot study.
    Melanoma Res 1996;6:399-401.

  • Budman D, Camacho E, Wittes R.
    The current causes of death in patients with malignant melanoma.
    Eur J Cancer 1978;14:327-330.

  • Coleman RE.
    Bisphosphonates: clinical experience.
    Oncologist 9 2004;14-27.

  • Dhopapkar M et al.
    Phase I trial of temozolomide in patients with advanced cancer.
    Clin Cancer Res 1997;3:1093-1100.

  • Doss L, Memula M.
    The radioresponsiveness of melanoma.
    Int J Radiat Oncol Biol Phys 1985;8:1131-1134.

  • Douglas JG, Margolin KA.
    The treatment of brain metastases from malignant melanoma.
    Semin Oncol 2002;29:518-524.

  • Falkson CI, Falkson G, Falkson HC.
    Phase II trial of fotemustine in patients with metastatic malignant melanoma.
    Invest New Drugs 1994;12:251-254.

  • Flickinger J et al.
    Radiosurgery: Its role in brain metastasis management.
    Neurosurg Clin North Am 1996;7:497-504.

  • Gaspar L et al.
    Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.
    Radiat Oncol Biol Phys 1997;37:745-751.

  • Geara F, Ang K.
    Radiation therapy for malignant melanoma.
    Surg Clin North Am 1996;76:1383-1399.

  • Geiger M et al.
    Response of intracranial melanoma metastases to sterotactic radiosurgery.
    Radiat Oncol Investig 1997;5:72-80.

  • Grob J et al.
    Radiosurgery without whole brain radiotherapy in melanoma brain metastases.
    Eur J Cancer 1998;34:1187-1192.

  • Hammond LA et al.
    Phase I and pharmacokinetics study of temozolomide on a dailyfor-5-days schedule in patients with advanced solid malignancies.
    J Clin Oncol 1999;17:2604-2613.

  • Hwu WJ et al.
    Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
    J Clin Oncol 2003;21:3351-3356.

  • Jacquillat C et al.
    Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.
    Cancer 1990;66:873-878.

  • Khayat D et al.
    Fotemustine in the treatment of brain primary tumors and metastases.
    Cancer Invest 1994;12:414-420.

  • Kleeberg UR et al.
    Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperation Group (MCG).
    Melanoma Res 1995;5:195-200.

  • Konefal J, Emami B, Pilepich M.
    Analysis of dose fractionation in the palliation of metastases from malignant melanoma.
    Cancer 1988;61:243-246.

  • Leksell L.
    The stereotaxic method and radiosurgery of the brain.
    Acta Chir Scand 1951;102:316-319.

  • Loeffler J, Barker F, Chapman P.
    Role of radiosurgery in the management of central nervous system metastases.
    Cancer Chemother Pharmacol 1999;43:11-14.

  • Margolin K et al.
    Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group.
    J Cancer Res Clin Oncol 2002;128:213-218.

  • McQuay HJ et al.
    Radiotherapy for the palliation of painful bone metastases.
    Cochrane Database Syst Rev 2: CD001793, 2000.

  • Mintz AH et al.
    A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis.
    Cancer 1996;78:1470-1476.

  • Mitchel MS.
    Relapse in the central nervous system in melanoma patients successfully trated with biomodulators.
    J Clin Oncol 1989;7:1701-1709.

  • Mornax F et al.
    A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
    Mel Res 2003;13:97-103.

  • Newlands ES et al.
    Temozolomide: Drug scheduling in vivo and in combination with radiation.
    Proc Am Soc Clin Oncol 1997;16:393a (abstract 1403).

  • Overgaard J.
    The role of radiotherapy in recurrend and metastatic malignant melanoma: A clinical radiobiological study.
    Int J Radiat Oncol Biol Phys 1986;12:867-872.

  • Overgaard J.
    Radiation treatment of malignant melanoma.
    Int J Radiat Oncol Biol Phys 1980;6:41-44.

  • Overgaard J, von der Maase H, Overgaard M.
    A randomized study comparing two highdose per fraction radiation schedules in recurrent or metastatic malignant melanoma.
    Int J Radiat Oncol Biol Phys 1985;11:1837-1839.

  • Patchell RA et al.
    A randomized trial of surgery in the treatment of single metastases to the brain.
    N Engl J Med 1990;322:494-500.

  • Patel M et al.
    Plasma and cerebrospinal fluid pharmacokinetics of temozolomide.
    Proc Am Soc Clin Oncol 1995;14:461 (abstract 1485).

  • Pirzkall AJ D et al.
    Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases.
    J Clin Oncol 1998;16:3563-3569.

  • Radbill AE et al.
    Initial treatment of melanoma brain metastases using gamma knife radiosurgery.
    Cancer 2004;101:825-833.

  • Sampaio EP et al.
    Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
    J Exp Med 1991;173:699-703.

  • Sampson J et al.
    Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.
    J Neurosurg 1998;88:11-20.

  • Sause W et al.
    Fraction size in external beam radiation therapy in the treatment of melanoma.
    Int J Radiat Oncol Biol Phys 1991;20:429-432.

  • Sause W et al.
    Solitary brain metastasis: Results of an RTOG/SWOG protocol evaluation surgery + RT versus RT alone.
    Am J Clin Oncol 1990;13:427-432.

  • Schoeggl A et al.
    Prognostic factor analysis for multiple brain metastases after gamma knife radiosurgery: Results in 97 patients.
    J Neurooncol 1999;42:169-175.

  • Seegenschmiedt MH et al.
    Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience.
    Int J Radiat Oncol Biol Phys. 1999;44:607-18.

  • Selek U et al.
    Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases.
    Int J Radiat Oncol Biol Phys 2004;59:1097-1106.

  • Seung S et al.
    Gamma knife radiosurgery for malignant melanoma brain metastases.
    Cancer J Sci Am 1998;4:103-109.

  • Shaw E et al.
    Single dose radiosurgery treatment of reccurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05.
    Int J Radiat Oncol Biol Phys 2000;47:291-298.

  • Shiau C et al.
    Radiosurgery for brain metastases: Relationship of dose and pattern of enhancement to local control.
    Int J Radiat Oncol Biol Phys 1997;37:375-383.

  • Siena S et al.
    A phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer and non-small cell lung cancer.
    Proc Am Soc Clin Oncol 2003;22:102 (abstract 407).

  • Smalley S et al.
    Resection for solitary brain metastasis.
    J Neurosurg 1992;77:531-540.

  • Somoza S et al.
    Sterotactic radiosurgery for cerebral metastastic melanoma.
    J Neurosurg 1993;79:661-666.

  • Sperduto PW et al.
    Stereotactic radiosurgery with whole brain radiation therapy improves survival in patients with brain metastases: Report of Radiation Oncology Group Phase III Study 95-08.
    Int J Radiation Biol Physics 2002;54:Plenary 5.

  • Strauss A et al.
    Radiation therapy of malignant melanomas: An evaluation of clinically used fractionated schemes.
    Cancer 1981;47:1262-1266.

  • Stupp R et al.
    Daily temozolomide and concomitant radiotherapy followed by adjuvant TMZ for newly diagnosed glioblastoma multiforme: A well-tolerated and promising regimen.
    Proc Am Soc Clin Oncol 1999;18:154a (abstract 592).

  • Tonsoni A, Lumachi F, Brandes AA.
    Treatment of brain metastases in uncommon tumors.
    Expert Rev Anticancer Ther 2004;4:794-793.

  • Vecht CJ et al.
    Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33:583-590.

  • Williams J et al.
    Sterotactic radiosurgery for brain metastses: Comparision of lung carcinoma vs. non-lung tumors.
    J Neurooncol 1998;37:79-85.

  • Wronski M, Arbit E.
    Surgical treatment of brain metastases from melanoma: A retrospective study of 91 patients.
    J Neurosurg 2000;93:9-18.

  • Young R.
    Radiosurgery for the treatment of brain metastases.
    Semin Surg Oncol 1998;14:70-78.

Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"; Publikation als Buch: Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch: